awmsg logo



icatibant acetate (Firazyr®)


Reference No. 3293

Publication date:
12/06/2018


Appraisal information

icatibant acetate (Firazyr®) 30 mg solution for injection


Company: Shire Orphan Therapies GmbH
BNF category: Respiratory system
NMG meeting date: 11/04/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0818
Ratification by Welsh Government: 11/06/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Icatibant acetate (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download